Asciminib was further investigated in the ASCEMBL study (NCT03106779), an ongoing, international, open‐label, randomized, active‐controlled, phase 3 study in patients with CML‐CP (not harboring the BCR::ABL1 T315I or V299L mutations) who were previously treated with ≥2 TKIs.24 This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.